Patients ( n = 27 ) in the abagovomab arm without CA125-specific CTL but that developed Ab3 above the cutoff ( defined as median Ab3 level at week 22 ) had a prolonged RFS compared to patients ( n = 24 ) that did not develop Ab3 above the cutoff ( log-rank test p = 0.019 ) .